1. Home
  2. SLXN vs BBGI Comparison

SLXN vs BBGI Comparison

Compare SLXN & BBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • BBGI
  • Stock Information
  • Founded
  • SLXN 2008
  • BBGI 1961
  • Country
  • SLXN Israel
  • BBGI United States
  • Employees
  • SLXN N/A
  • BBGI N/A
  • Industry
  • SLXN
  • BBGI Broadcasting
  • Sector
  • SLXN
  • BBGI Consumer Discretionary
  • Exchange
  • SLXN NYSE
  • BBGI Nasdaq
  • Market Cap
  • SLXN 7.3M
  • BBGI 8.1M
  • IPO Year
  • SLXN N/A
  • BBGI 2000
  • Fundamental
  • Price
  • SLXN $0.80
  • BBGI $4.08
  • Analyst Decision
  • SLXN Strong Buy
  • BBGI
  • Analyst Count
  • SLXN 1
  • BBGI 0
  • Target Price
  • SLXN $5.00
  • BBGI N/A
  • AVG Volume (30 Days)
  • SLXN 141.1K
  • BBGI 85.2K
  • Earning Date
  • SLXN 08-21-2025
  • BBGI 08-11-2025
  • Dividend Yield
  • SLXN N/A
  • BBGI N/A
  • EPS Growth
  • SLXN N/A
  • BBGI N/A
  • EPS
  • SLXN N/A
  • BBGI N/A
  • Revenue
  • SLXN N/A
  • BBGI $234,823,730.00
  • Revenue This Year
  • SLXN N/A
  • BBGI $5.02
  • Revenue Next Year
  • SLXN N/A
  • BBGI N/A
  • P/E Ratio
  • SLXN N/A
  • BBGI N/A
  • Revenue Growth
  • SLXN N/A
  • BBGI N/A
  • 52 Week Low
  • SLXN $0.58
  • BBGI $3.67
  • 52 Week High
  • SLXN $41.85
  • BBGI $14.95
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • BBGI 39.59
  • Support Level
  • SLXN N/A
  • BBGI $3.67
  • Resistance Level
  • SLXN N/A
  • BBGI $4.17
  • Average True Range (ATR)
  • SLXN 0.00
  • BBGI 0.32
  • MACD
  • SLXN 0.00
  • BBGI 0.02
  • Stochastic Oscillator
  • SLXN 0.00
  • BBGI 25.79

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About BBGI Beasley Broadcast Group Inc.

Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The company operates in two segments Audio and Digital.

Share on Social Networks: